Clinical trial operations generate a continuous stream of documents that move between sponsors, contract research organizations (CROs), research sites, IRBs, and regulatory agencies. Protocol amendments, informed consent forms, adverse event reports, laboratory results, and regulatory submissions all require secure, trackable transmission with a documented record of when each document was sent and received.
Fax has remained a primary channel for many of those transmissions because it satisfies requirements that other methods do not consistently meet: a legally defensible transmission record, cross-organization compatibility, and encryption standards that apply to protected health information under HIPAA and participant data under ICH Good Clinical Practice (GCP) guidelines.
What Compliance Requires
Research sites and sponsors operating under FDA oversight and ICH GCP guidelines are required to maintain complete and accurate records of all clinical trial communications. For document transmissions, that means being able to produce a record of when a document was sent, what was transmitted, to whom it was sent, and when it was received.
A physical fax machine produces a transmission report, but that report is a printed page that can be misfiled, lost, or unavailable at audit time. A modern fax platform like Passport produces a digital audit trail that is stored in the system, searchable, and available without relying on a paper record surviving intact until the trial’s inspection period closes.
For trials subject to FDA inspection, that difference is significant. An auditor asking to see transmission records for a serious adverse event report should be able to receive that documentation quickly and completely. A system that logs every transmission with a timestamp, sender, recipient, and delivery confirmation makes that response straightforward.
HIPAA and Participant Data
Clinical trial participants are patients, and their health information is protected under HIPAA whether they are receiving investigational treatment or standard care. Research sites that transmit participant data to sponsors or central laboratories are subject to the same HIPAA technical safeguard requirements that apply to any healthcare provider transmitting PHI.
Passport is built for HIPAA-compliant transmission. All faxes are encrypted in transit, delivery is confirmed and logged, and the etherFAX network that powers Lane’s cloud-based faxing is HITRUST certified. For research sites that need to demonstrate HIPAA compliance to their IRB, sponsor, or a federal auditor, the platform’s compliance architecture is documented and verifiable.
The FAQ Friday post on fax security and privacy covers the specific encryption and data handling approach in detail.
Adverse Event Reporting and Protocol Amendments
Two of the highest-stakes fax workflows in clinical trial operations are adverse event reporting and protocol amendment distribution. Both have defined timelines, both require documentation that transmission occurred, and both carry regulatory consequences if the documentation cannot be produced.
For serious and unexpected adverse events, FDA regulations require sponsors to notify the FDA and all participating investigators within defined timeframes. That notification frequently travels by fax. Passport’s delivery confirmation and audit log function as the documentation that notification occurred, without requiring a manual log entry or a return call from every recipient.
Protocol amendments move in the opposite direction, from sponsor or CRO to each research site, and each site must acknowledge receipt before implementing the amendment. Passport’s transmission confirmation provides the record that the amendment reached each site, and the timestamp on that confirmation documents when the site received it.
Multi-Site Trial Operations
Sponsors and CROs managing trials across multiple research sites are coordinating document distribution to sites that may be in different states or different countries, on different EHR platforms, and with different internal fax configurations. The receiving infrastructure at each site varies. What cannot vary is whether the transmission reaches its destination and whether there is a record of that delivery.
Passport’s scalability across multi-site environments and its compatibility with a wide range of receiving infrastructure means that the sending side of a multi-site trial communication can use a centralized, auditable platform regardless of what is on the receiving end. Faxes to traditional analog machines at community research sites and to enterprise fax platforms at academic medical centers route through the same Passport deployment and generate the same audit trail.
For research sites that are also deploying ERIS for EHR integration, the same platform that manages clinical faxing can handle trial-related document transmission within the same compliance framework.
Schedule a strategy call with the Lane team to discuss how Passport supports compliant document transmission in clinical trial environments.
